UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (date of earliest event reported): January 17, 2012

OPEXA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)

Texas		001-33004		76-0333165
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

2635 Technology Forest Blvd., The Woodlands, Texas	77381
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (281) 272-9331

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

⃞ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

On January 17, 2012, Opexa Therapeutics, Inc. (the “Company”) issued a press release announcing that Neil K. Warma, the Company’s President and Chief Executive Officer, will deliver a corporate presentation at the BOCEMb; Noble Financial Capital Markets’ Eighth Annual Equity Conference.  The Company’s presentation will take place at 1:30 p.m. (EST) on Wednesday, January 18, 2012, in Hollywood, Florida.  The presentation will include an overview of the Company’s ongoing clinical development program for Tovaxin®, the Company’s lead therapy for multiple sclerosis.  The presentation will be webcasted and the link to access the audio webcast and the presentation materials will be available at the Investor Relations page of the Company’s website at www.opexatherapeutics.com.

Item 9.01     Financial Statements and Exhibits

(d)  Exhibits

Exhibit No.	Description

99.1	Press release issued January 17, 2012 by Opexa Therapeutics, Inc.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated:	January 17, 2012	OPEXA THERAPEUTICS, INC.


		By:	/s/ Neil K. Warma
			Neil K. Warma
			President & Chief Executive Officer

Exhibit No.	Description

99.1	Press release issued January 17, 2012 by Opexa Therapeutics, Inc.